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Background: Currently, clinical trials for new therapeutic strategies are being planned for Duchenne and Becker
muscular dystrophies (DMD/BMD). However, it is difficult to obtain adequate numbers of patients in clinical trials. As
solutions to these problems, patient registries are an important resource worldwide, especially in rare diseases such
as DMD/BMD.
Methods: We developed a national registry of Japanese DMD/BMD patients in collaboration with TREAT-NMD. The
registry includes male Japanese DMD/BMD patients whose genetic status has been confirmed by genetic analysis.
The registry includes patients throughout Japan.
Results: As of February 2012, 583 DMD and 105 BMD patients were registered. Most individuals aged less than
20 years. In terms of genetic mutations of registrants of DMD and BMD, deletion of exons was the most frequent
(61.4% and 79.0%) followed by point mutations (24.5% and 14.3%) and duplications (13.6% and 4.8%), respectively.
43.6% of DMD are capable of walking, and 76.2% of BMD registrants are able to walk. 41.1% of DMD registrants in
the database were treated using steroids. 29.5% of DMD and 23.8% of BMD registrants were prescribed one cardiac
medicine at least. 22% of DMD used ventilator support, and non-invasive support was common. Small numbers of
DMD and BMD registrants, only 3.9% and 1.0% of them, have received scoliosis surgery. 57 (9.8%) patients were
eligible to clinical trial focused on ‘skipping’ exon 51.
Conclusions: The Remudy has already demonstrated utility in clinical researches and standardization of patients
care for DMD/BMD. This new DMD/BMD patient registry facilitates the synchronization of clinical drug development
in Japan with that in other countries.
Keywords: Duchenne and Becker muscular dystrophy, Neuromuscular disorder, National registry, TREAT-NMD,
Registry of muscular dystrophy (Remudy), JapanIntroduction
Duchenne muscular dystrophy (DMD) and Becker muscu-
lar dystrophy (BMD) are X-linked recessive forms of mus-
cular dystrophy caused by mutations in the dystrophin
gene (DMD) on chromosome Xp21.2 [1]. The DMD gene
is the largest gene identified in human and contains 79
exons. Mutations in this gene cause deficiency of normal* Correspondence: enkimura@ncnp.go.jp
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reproduction in any medium, provided the ordystrophin protein [2]. DMD is the most frequently
inherited muscular disease, affecting approximately 1 out
of 3500 live male new-borns. DMD patients commonly
lose their ability to walk before the age of 12 years,
coupled with deterioration in respiratory and cardiac func-
tions. DMD is usually fatal in the third decade because of
either cardiac or respiratory failure. On the other hand,
the course and severity of BMD is more variable [3]. Since
the discovery of the dystrophin gene, many efforts have
been made to develop effective therapeutic strategies for
DMD/BMD.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DMD/BMD [4-8]; however, many challenges exist with re-
gard to both planning and conducting clinical trials for
such rare diseases. Because of limited epidemiological
data, the total number of patients, natural history of the
disease and clinical outcome measures are unclear. In
addition, adequate numbers of patients are needed to
achieve significant results in clinical trials. As solutions to
these problems, patient registries are an important re-
source especially in case of rare diseases such as DMD/
BMD.
In Europe, Translational Research in Europe–Assessment
and Treatment of Neuromuscular Diseases (TREAT-NMD)
[9], a research network for neuromuscular disorders, de-
veloped a global database for DMD and spinal muscular
atrophy (SMA) to obtain epidemiological data; examine
the total number of patients; determine the natural history
of the disease; determine appropriate clinical outcome
measures and collect adequate numbers of patients needed
to achieve significant results in clinical trials and inform
patients of new drug development as soon as possible.
To date, several Japanese DMD/BMD databases have
been developed [10-12]; however, these have not been
on a broad national scale. For instance, some were on a
single-centre basis and others encompassed only a small
local area or several hospital sites. Some others were re-
stricted to inpatients only. Despite these early efforts, no
national registry has been developed with the purpose of
focusing on clinical trials. In 2009, we developed a na-
tional registry of Japanese DMD/BMD patients (REgistry
of MUscular DYstrophy; Remudy. http://www.remudy.
jp/) in collaboration with TREAT-NMD. The purpose of
this registry was to effectively recruit eligible patients to
new clinical trials and provide timely information to pa-
tients about upcoming trials. Registry data also provides
more detailed knowledge about the natural history and
epidemiology of the disease, as well as information about
clinical care. In this paper, we introduce Remudy, the
Japanese DMD/BMD registry, and describe the clinical
and molecular genetic characteristics of Japanese
dystrophinopathy patients.
Materials and methods
Institution, organization and leadership
Remudy is supported by a Research Grant (20B-12, 23–4)
for Nervous and Mental Disorders from the Ministry of
Health, Labour and Welfare. The development and man-
agement of the registry is led by the principal investigator
of the Japanese muscular dystrophy research group.
Steering committee members include scientists, clinicians
and representatives of patient organizations. The office of
the registry of muscular dystrophy was set up within the
National Center of Neurology and Psychiatry (NCNP),
Tokyo, Japan. This project includes Japanese DMD/BMDpatients and was made possible by collaboration with the
Japan Muscular Dystrophy Association.
Patients
The database includes male Japanese DMD/BMD patients
whose genetic status has been confirmed by genetic ana-
lysis. The database includes patients throughout Japan.
The cost of sequencing analysis of the DMD gene is not
covered by the system of the public health insurance in
Japan. For patients who intend to register but whose gen-
etic status is not confirmed using multiplex ligation-
dependent probe amplification (MLPA), Remudy provides
free service of sequencing analysis of the DMD gene.
Method of registration and data collection
Information about the registry was provided to inter-
ested individuals and their informed consent was
obtained. Provision of all data by patients is voluntary
and is not shared with any third party without the per-
mission of the committee responsible for disclosing the
information. Inclusion in the database confers no obliga-
tion for the patient, and they may be removed from the
registry immediately on request. It was stated that re-
fusal to participate would not affect the subsequent
medical care of the patient. This study was approved by
Institutional Review Board of National Center of Neur-
ology and Psychiatry, Japan.
Structure of the registry form
Data obtained via the registry form included clinical symp-
toms, results of biochemistry, muscle biopsy and other la-
boratory analysis and description of the genetic mutation.
Epidemiological information provided includes walking
capability, cardiac and respiratory functions, creatine kin-
ase levels, history of scoliosis surgery and steroid therapy
status. All these data should be confirmed by molecular
and clinical curators in Remudy (three active molecular
and three active clinical curators). The structure of the
Case Report Form and registry items are shown in Table 1.
Information was annually updated by registrant’s self re-
port after their physician’s confirmation following reminder
from registration office. To decide whether a patient was
classified as DMD or BMD, first, attending physician made
a diagnosis whether a patient was DMD or BMD by the
clinical and molecular information. Then, when our clin-
ical and genetic curators double-checked their classifica-
tion by reviewing clinical information, and also data from
pathological (including dystrophin immuno-staining, if ap-
plicable) and genetic analysis.
Results
As of February 2012, 876 Japanese patients across Japan
had sought registration, and 583 DMD and 105 BMD
patients were registered based on their eligibility as
Table 1 The report form for registry to Remudy
Contact Clinical data
-Name -Data
-ID number -Muscle biopsy
-Hospital •Examed/not examed
-Date of birth •Dystrophin immunostain
-Address -Walking capability
-Phone •Ambulant /wheelchair
-E-mail -Use steroid therapy
-Signed up for other
registries
-Cardiac function
-Attending any clinical
trials
•LVEF(%)
-Registering other
database
•Medication
Diagnosis -Respiratory function
-DMD/BMD/IMD •FVC
-Proof of the diagnosis •Mechanical support
•Genetic
confirmed
-Scoliosis surgery
•Muscle biopsy -CK level
•Suspected from
family history
-Weight
•Others Molecular genetic data (certificated report
should be attached)
-Method
•MLPA/Multiplex PCR/southern blot/RT-
PCR/ Direct sequencing of exons
-Type of mutation
•Deletion/duplication/others
•Details of the mutation
DMD, Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; IMD,
Intermediate muscular dystrophy; MLPA, Multiplex ligation-dependent probe
amplification; LVEF, Left ventricular ejection fraction; FVC, Forced vital capacity;
CK, Creatine kinase.
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Figure 1 Ages of registered individuals. Most registrants are under 20 y
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(Figure 1, Figure 2 and Table 2). Most individuals aged
less than 20 years; however, several registered individuals
were aged over 35 years. There are five patients between
45 and 49 years old in DMD. The molecular data of four
patients are consistent with reading frame rule, and
these patients became bedridden with tracheotomy in
muscular dystrophy care ward. A molecular data of an-
other patient isn’t consistent with DMD mutation (in-
frame mutation, del 10–42), however he lost his walking
ability in childhood and had a tracheotomy. His attend-
ing doctor clinically diagnosed him as DMD. In terms of
genetic mutations of registrants of DMD and BMD,
deletion of exons was the most frequent (61.4% and
79.0%) followed by point mutations (24.5% and 14.3%)
and duplications (13.6% and 4.8%), respectively. Most
registered patients lived in cities, namely Tokyo, Osaka
and Nagoya (Figure 3).
Tables 3 describe the clinical characteristics of Japanese
DMD/BMD patients included in the registry. The infor-
mation collected was similar to that for the core items re-
quired for the TREAT-NMD global registry, and thus, we
will be able to compare Japanese data with those
contained in the global registry.
Among the DMD registrants, 43.6% of them are capable
of walking. On the other hand, 76.2% of BMD registrants
are able to walk. In terms of cardiac and respiratory func-
tion, 67.2% of DMD and 72.4% of BMD have normal car-
diac function and respiratory functional examination was
not performed among half of DMD registrants. It was sug-
gested that many registrants were too young to be tested
when they were registered. 41.1% of DMD registrants in
the database were treated using steroids. 29.5% of DMD
and 23.8% of BMD registrants were prescribed one cardiac
medicine at least, and ACE–inhibitor was the most com-
mon medicine for cardiac failure. One fifth of DMD used
ventilator support, and among the registrants with3 12
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Figure 2 Frequency of deleted exons observed in registrants with DMD and BMD. Distribution of exon deletion shows common hot spot
regions in exons 45–54 in DMD and BMD.
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mon. Small numbers of DMD and BMD registrants, only
3.9% and 1.0% of them, have received scoliosis surgery.
The Remudy registry has already demonstrated utility in
clinical trials for DMD/BMD. A clinical trial focused on
‘skipping’ exon 51 using antisense oligonucleotides hasTable 2 Distribution of mutations in the registrants with
DMD and BMD
DMD patients BMD patients
No. of
case
% of
cases
No. of
case
% of
cases
Distribution of
mutation
Deletion 358 61.4% 83 79.0%
Duplication 79 13.6% 5 4.8%
Deletion and
Duplication
1 0.2% 0 0.0%
Others * 144 24.7% 15 14.3%
No mutation found** 1 0.2% 2 1.9%
583 100.0% 105 100.0%
* Others include nonsense mutations, small insertion/deletion mutations, deep
intronic mutations, and splice site mutations.
** Their diagnosis was confirmed based on their pathological findings in
muscle biopsy including a negative immunohistochemical staining
against dystrophin.been recently conducted in Japan. From the Remudy
registry data, 57 (9.8%) patients have mutations theoretic-
ally addressable by skipping of exon 51 (Table 4).
Discussion
The DMD/BMD registry run by Remudy is the one of its
kind in Japan specifically targeting neuromuscular dis-
eases. It is the first national registry in Japan to include
both clinical and molecular genetic data, and its utility in
promoting clinical trials has been demonstrated. Prior to
the development of Remudy, some DMD/BMD databases
existed in Japan [10-12]; however, they were limited in
their coverage and utility. This is the first Japanese DMD/
BMD database aimed at facilitating clinical trials and the
first to coordinate with a global database.
Since 2011, a worldwide phase III, randomized, double-
blind, placebo-controlled clinical study is being conducted
for patients with DMD who have a DMD gene mutation
amenable to an exon 51 skip. Partially because of the de-
velopment of the Remudy database, this trial now includes
Japanese sites and is thus the first global clinical trial to
become available to Japanese DMD patients. Up until
now, clinical trials for DMD under new International Con-
ference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use–Good
<5
5 and over
10 and over
20 and over
40 and over
TokyoOsaka Nagoya
Figure 3 Prefectural distribution of the registrants. There are 47 prefectures in Japan. Individuals from all rural areas in Japan were registered
but most registrants were concentrated in big cities, namely Tokyo, Osaka and Nagoya.
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Japan. Registry information concerning eligible Japanese
individuals was sought by TREAT-NMD and pharmaceut-
ical companies and has been provided with permission.
This example demonstrates the usefulness of the registry
for facilitating patient access to clinical trials, as well as en-
hancing recruitment for such trials.
Another novel aspect is patient participation in the
registration process. Previously, database information was
supplied by clinicians. In contrast, the Remudy system en-
ables patients themselves to provide their information to
the registry in collaboration with their clinicians. The
registry consists of valuable clinical and genetic data,
which yields valuable epidemiological information includ-
ing walking capability, cardiac and respiratory functions,
creatine kinase levels, history of scoliosis surgery and ster-
oid therapy status, all of which are needed to plan clinical
trials and determine the eligibility of individuals for such
trials. This has resulted in Remudy becoming one of the
largest and most reliable rare disease registries in Japan.
Remudy also reveals the structure of mutations in
Japanese DMD/BMD patients. The distribution of muta-
tions and the frequency of individual exon deletion found
in our study are consistent with previous reports. In
DMD, distribution, duplication and point mutations com-
prise 61.4%, 13.6% and 24.5%, respectively. Distribution of
exon deletions reveals significant region in exons 42–54
(Figure 2). This is similar to the findings of other databases
[13] and those of a Japanese study in a single referral
centre [11].
Because of improvements in respiratory and cardiac
complications, life expectancy of Japanese DMD patientshas been prolonged [14]. Our findings support this, with
the Remudy registry including several individuals over
40 years of age (though most were aged <20 years).
41.1% of DMD patients in the database were treated
using steroids. Importantly, this ratio may be relatively
low compared to that in western countries, considering
that the family guide for the diagnosis and management
of DMD became available to download in Japanese in
2011 [15]. Given that this treatment is recommended in
the guide, the number of individuals being treated with
steroids for DMD may increase in future.
Remudy is intended to be used as a public service for
the benefit of patients living with neuromuscular dis-
eases. Through participation in the database, patients
may be identified as candidates for upcoming clinical tri-
als. In addition, Remudy has provided additional useful
resources for patients through a website and newsletter.
The information provided via these methods includes
the development of new therapeutic compounds, infor-
mation regarding care standards (known as the Family
Guide for the Diagnosis and Management of Duchenne
Muscular Dystrophy [15]) and other relevant medical in-
formation. In addition, Remudy has facilitated the gen-
etic diagnosis and detailed sequencing analysis of
individuals, thereby promoting genetic counseling in
family and also providing important information re-
quired to determine eligibility for clinical trials. As a re-
sult, more dystrophinopathy patients have become aware
of the necessity of confirming their diagnosis via analysis
of the DMD gene.
The development of Remudy is part of a global trend to-
ward database development for neuromuscular disorders.
Table 3 Clinical manifestations, medications and
intervention characteristics in the registrants with DMD
and BMD
DMD patients BMD patients
No. of
case
% of
cases
No. of
case
% of
cases
Walking capability
Normal walking 254 43.6% 80 76.2%
Not able to walk, and sit without
support
184 31.6% 19 18.1%
Not able to sit without support 145 24.9% 6 5.7%
583 100.0% 105 100.0%
Cardiac function
Normal 392 67.2% 76 72.4%
Dysfunction 180 30.9% 28 26.7%
Not performed 11 1.9% 1 1.0%
583 100.0% 105 100.0%
Respiratory function
Normal 65 11.1% 45 42.9%
Dysfunction 202 34.6% 18 17.1%
Not performed 316 54.2% 42 40.0%
583 100.0% 105 100.0%
Steroid use
Current 171 29.3% 6 5.7%
Used to 69 11.8% 6 5.7%
Never 343 58.8% 93 88.6%
583 100.0% 105 100.0%
Cardiac medication
Prescribed 172 29.5% 25 23.8%
Not prescribed 411 70.5% 80 76.2%
583 100.0% 105 100.0%
Drug
β-blocker 94 54.7% 16 64.0%
ACE-inhibitor 140 81.4% 19 76.0%
ARB 12 7.0% 5 20.0%
Diuretics 43 25.0% 7 28.0%
Other 29 16.9% 7 28.0%
172*1 100% 25*1 100%
Mechanical ventilation
No 455 78.0% 103 98.1%
Yes 128 22.0% 2 1.9%
583 100.0% 105 100.0%
Invasive 20 15.6% 2 100.0%
Non-invasive 108 84.4% 0 0.0%
128*2 100.0% 2*2 100.0%
Temporal 71 55.5% 0 0.0%
Continuous 57 44.5% 2 100.0%
128*2 100.0% 2*2 100.0%
Table 3 Clinical manifestations, medications and
intervention characteristics in the registrants with DMD
and BMD (Continued)
Scoliosis surgery
Yes 23 3.9% 1 1.0%
No 560 96.1% 103 98.1%
Not described 0 0.0% 1 1.0%
583 100.0% 105 100.0%
*1; The number of registrants who were prescribed with
cardiovascular medicines.
*2; The number of registrants using ventilator support.
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neuromuscular disorders and has been leading inter-
national registry collaboration for many diseases including
DMD, spinal muscular atrophy, myotonic dystrophy type 1
and others. Close collaboration with TREAT-NMD has
allowed Japan to enhance the management and care of
Japanese DMD and BMD patients and facilitated research
in neuromuscular disorders. One of the most important
outcomes of this collaboration is the development of the
Japanese national registry for DMD described in this
paper. By collecting common information, the registry
data can easily be compared between Japan and other
countries. TREAT-NMD has helped to support these ef-
forts by providing an infrastructure that continues to ac-
celerate research, therapy development, and trial readiness
in addition to increasing collaboration and improving pa-
tient care. Japanese patients, families, physicians and any-
one affected by a neuromuscular disorder play a key role
in the worldwide neuromuscular community by participat-
ing in this collaboration with TREAT-NMD, which is
Remudy.
The TREAT-NMD global registry has been focused on
European countries and the United States; however, it is
currently expanding to other countries. Rare disease regis-
tries are emerging in Asian countries [16] and Japanese ex-
periences in collaboration with TREAT-NMD and registry
development should be able to provide more information
about these activities to Asian countries. A global registryTable 4 Applicable individuals for exon 51 skipping
clinical trial
Deleted exons No. of individuals % in registrants
45-50 17 2.9%
47-50 0 0.0%
48-50 9 1.5%
49-50 18 3.1%
50 6 1.0%
52 7 1.2%
52-63 0 0.0%
total 57 9.8%
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launched in the near future [17]. Several other registries
for neuromuscular diseases have been developed world-
wide, such as the international congenital muscular
dystrophy registry (CMDIR) run by the US patient
organization ‘Cure CMD’. Remudy has been developing
Japanese registries for other neuromuscular diseases
including glucosamine (UDP-N-acetyl)–2-epimerase/N-
acetylmannosamine kinase (GNE) myopathy and myo-
tonic dystrophy type 1 (DM1).
We have thus demonstrated how this registry can en-
hance the readiness for clinical trials in Japan, and how
this unique form of infrastructure can be used to accel-
erate international efforts in fighting orphan diseases.
Conclusions
The Remudy registry has already demonstrated utility in
clinical trials and standardization of patients care for
DMD/BMD. This new DMD/BMD patient registry will fa-
cilitate the synchronization of clinical drug development
in Japan with that in other countries.
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